- Home
- AKBA vs PANL Comparison
AKBA vs PANL Comparison
Compare AKBA & PANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- PANL
- Stock Information
- Founded
- AKBA 2007
- PANL 1996
- Country
- AKBA United States
- PANL United States
- Employees
- AKBA N/A
- PANL N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- PANL Marine Transportation
- Sector
- AKBA Health Care
- PANL Consumer Discretionary
- Exchange
- AKBA Nasdaq
- PANL Nasdaq
- Market Cap
- AKBA 336.2M
- PANL 289.9M
- IPO Year
- AKBA 2014
- PANL N/A
- Fundamental
- Price
- AKBA $1.91
- PANL $6.63
- Analyst Decision
- AKBA Strong Buy
- PANL Strong Buy
- Analyst Count
- AKBA 2
- PANL 1
- Target Price
- AKBA $5.75
- PANL N/A
- AVG Volume (30 Days)
- AKBA 2.3M
- PANL 155.8K
- Earning Date
- AKBA 11-07-2024
- PANL 11-15-2024
- Dividend Yield
- AKBA N/A
- PANL 6.00%
- EPS Growth
- AKBA N/A
- PANL N/A
- EPS
- AKBA N/A
- PANL 0.77
- Revenue
- AKBA $169,879,000.00
- PANL $503,739,510.00
- Revenue This Year
- AKBA N/A
- PANL $6.40
- Revenue Next Year
- AKBA $3.23
- PANL $15.67
- P/E Ratio
- AKBA N/A
- PANL $8.69
- Revenue Growth
- AKBA N/A
- PANL N/A
- 52 Week Low
- AKBA $0.80
- PANL $6.00
- 52 Week High
- AKBA $2.48
- PANL $9.53
- Technical
- Relative Strength Index (RSI)
- AKBA 68.47
- PANL 55.49
- Support Level
- AKBA $1.30
- PANL $6.16
- Resistance Level
- AKBA $2.01
- PANL $6.46
- Average True Range (ATR)
- AKBA 0.12
- PANL 0.15
- MACD
- AKBA 0.04
- PANL 0.04
- Stochastic Oscillator
- AKBA 78.52
- PANL 78.62
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About PANL Pangaea Logistics Solutions Ltd.
Pangaea Logistics Solutions Ltd and its subsidiaries provide seaborne drybulk transportation services. It transports drybulk cargos including grains, coal, iron, ore, pig, iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The firm's services include cargo loading, cargo discharge, vessel chartering, voyage planning and technical vessel management. The company derives all of its revenues from contracts of affreightment, voyage charters and time charters.